Entero Therapeutics Delays 10-K Filing

Story Highlights
Entero Therapeutics Delays 10-K Filing

Entero Therapeutics ( (ENTO) ) has released a notification of late filing.

Entero Therapeutics, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the ongoing review of the accounting treatment of a significant transaction, which requires additional time to ensure compliance with relevant accounting standards. The company anticipates filing the report within fifteen calendar days following the original due date. Entero Therapeutics does not expect any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Anna Skowron, the Interim Chief Financial Officer, who assured stakeholders of the company’s commitment to maintaining compliance.

More about Entero Therapeutics

YTD Price Performance: -26.15%

Average Trading Volume: 232,616

Technical Sentiment Signal: Buy

Current Market Cap: $2.28M

For a thorough assessment of ENTO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App